$3500 | Single User
$7000 | Site License
$10500 | Enterprise License

Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Pipeline Review, H2 2016
[Lowest Price Guaranteed: $3,500]

Published by Global Markets Direct: 09 Nov 2016 | 31934 | In Stock
Related Topics: Drug

Introduction

Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Pipeline Review, H2 2016’, provides in depth analysis on Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) targeted pipeline therapeutics.

The report provides comprehensive information on the Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

*Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5)

- The report reviews Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) targeted therapeutics and enlists all their major and minor projects

- The report assesses Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents
for Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Pipeline Review, H2 2016

  • Table of Contents

    Table of Contents 2

    List of Tables 4

    List of Figures 5

    Introduction 6

    Global Markets Direct Report Coverage 6

    Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) Overview 7

    Therapeutics Development 8

    Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Products under Development by Stage of Development 8

    Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Products under Development by Therapy Area 9

    Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Products under Development by Indication 10

    Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Pipeline Products Glance 11

    Late Stage Products 11

    Early Stage Products 12

    Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Products under Development by Companies 13

    Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Products under Development by Universities/Institutes 15

    Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Therapeutics Assessment 17

    Assessment by Monotherapy/Combination Products 17

    Assessment by Mechanism of Action 18

    Assessment by Route of Administration 19

    Assessment by Molecule Type 20

    Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Companies Involved in Therapeutics Development 22

    Akshaya Bio Inc. 22

    Celgene Corporation 23

    Etubics Corporation 24

    OSE Immunotherapeutics 25

    Vaxon Biotech 26

    Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Drug Profiles 27

    ETBX-011 - Drug Profile 27

    Product Description 27

    Mechanism Of Action 27

    R&D Progress 27

    GI-6207 - Drug Profile 30

    Product Description 30

    Mechanism Of Action 30

    R&D Progress 30

    OSE-2101 - Drug Profile 32

    Product Description 32

    Mechanism Of Action 32

    R&D Progress 32

    Peptides to Activate CEACAM5 for Crohn's Disease - Drug Profile 35

    Product Description 35

    Mechanism Of Action 35

    R&D Progress 35

    Vaccine to Target CEA for Oncology - Drug Profile 36

    Product Description 36

    Mechanism Of Action 36

    R&D Progress 36

    Vbx-016 - Drug Profile 37

    Product Description 37

    Mechanism Of Action 37

    R&D Progress 37

    Vbx-026 - Drug Profile 38

    Product Description 38

    Mechanism Of Action 38

    R&D Progress 38

    Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Dormant Projects 39

    Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Discontinued Products 40

    Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Featured News & Press Releases 41

    Feb 22, 2016: First patients enrolled and dosed in the pivotal trial of Phase 3 of the immunotherapy Tedopi for advanced non-small cell lung cancer 41

    Feb 04, 2016: OSE Pharma Announces U.S. Initiation of Atalante 1, the Company’s Global, Pivotal Phase 3 Trial for Tedopi Immunotherapy in Non-Small Cell Lung Cancer 41

    Jan 06, 2016: OSE Pharma Announces Initiation of Its Pivotal Phase 3 Trial of Tedopi in Non-Small Cell Lung Cancer 42

    Sep 29, 2015: OSE Pharma to participate to the Large & Midcap Event in Paris on October 7-8, 2015 43

    Aug 05, 2015: Etubics Platform Shown to Significantly Increase Survival Of End Stage Colorectal Cancer Patients 43

    Jun 22, 2015: Vaxon Biotech granted Japanese patent for new cancer vaccine candidates 44

    May 28, 2015: OSE Pharma and Simbec-­Orion to participate in the 51st annual Meeting of the American Society of Clinical Oncology, May 29th to June 2nd 2015, Chicago 45

    Jan 29, 2015: OSE Pharma appoints Simbec-Orion to conduct its Tedopi Phase III international clinical trial in advanced lung cancer patients 45

    Sep 15, 2014: Texopi, a new ray of hope for lung cancer immunotherapy 46

    Jun 23, 2014: Agreement on Phase 3 Trial Protocol of OSE Pharma's OSE-2101 From the FDA and EMA 47

    May 28, 2014: Etubics Will Present Results of Its Colorectal Cancer Phase 1 and 2 Immunotherapy Trial at the Annual American Society of Clinical Oncology Meeting in Chicago 48

    Jun 04, 2013: OSE Pharma Announces A Grant From OSEO For Its Targeted Cancer Immune Therapy In Phase III 48

    May 06, 2013: Etubics Platform Generates Solid Immune Response In Colorectal Cancer Patients 49

    Apr 03, 2013: GlobeImmune Initiates Phase II Study Of New T Cell Stimulating Cancer Vaccine Targeting CEA In Patients With Metastatic Medullary Thyroid Cancer 50

    Feb 14, 2013: OSE Pharma Announces The Orphan Drug Status Granted In The US For OSE 2101 50

    Appendix 51

    Methodology 51

    Coverage 51

    Secondary Research 51

    Primary Research 51

    Expert Panel Validation 51

    Contact Us 51

    Disclaimer 52

Additional Details

Publisher

Global Markets Direct

Publisher Information

Reference

31934 | GMDHC0649TDB

Number of Pages

52

Report Format

PDF

Global Markets Direct Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Pipeline Review, H2 2018
Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconi...
14 Aug 2018 by Global Markets Direct USD $3,500 More Info
Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Pipeline Review, H1 2018
Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconi...
20 Feb 2018 by Global Markets Direct USD $3,500 More Info
Global and Chinese Carcinoembryonic Antigen Industry, 2017 Market Research Report
The 'Global and Chinese Carcinoembryonic Antigen Industry, 2012-2022 Market Research Report' is a pr...
29 Dec 2017 by Prof Research USD $3,000 More Info
Carcinoembryonic Antigen (CEA) 2017-2021: US, Europe, Japan--Opportunities for Suppliers, Market Segment Forecasts and Shares, Competitive Strategies, Emerging Technologies, Instrumentation Review
The cancer diagnostics market is on the verge of explosion, as the researchers approach major techno...
09 Dec 2017 by Venture Planning Group (VPG) USD $4,350 More Info
Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Pipeline Review, H2 2017
Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconi...
29 Aug 2017 by Global Markets Direct USD $3,500 More Info
Carcinoembryonic Antigen (CEA) 2017-2021: US, Europe, Japan--Opportunities for Suppliers, Market Segment Forecasts and Shares, Competitive Strategies, Emerging Technologies, Instrumentation Review
The cancer diagnostics market is on the verge of explosion, as the researchers approach major techno...
30 Mar 2017 by Venture Planning Group (VPG) USD $4,350 More Info
Carcinoembryonic Antigen (CEA) 2017-2021: US, Europe, Japan--Opportunities for Suppliers, Market Segment Forecasts and Shares, Competitive Strategies, Emerging Technologies, Instrumentation Review
The cancer diagnostics market is on the verge of explosion, as the researchers approach major techno...
09 Dec 2016 by Venture Planning Group (VPG) USD $2,800 More Info
Carcinoembryonic Antigen (CEA) 2017-2021: US, Europe, Japan--Opportunities for Suppliers, Market Segment Forecasts and Shares, Competitive Strategies, Emerging Technologies, Instrumentation Review
The cancer diagnostics market is on the verge of explosion, as the researchers approach major techno...
09 Dec 2016 by Venture Planning Group (VPG) USD $4,350 More Info
Carcinoembryonic Antigen (CEA): US, Europe, Japan--Market Analysis, Competitive Intelligence, Technology Trends, Opportunities for Suppliers
The cancer diagnostics market is on the verge of explosion, as the researchers approach major techno...
24 Jun 2016 by Venture Planning Group (VPG) USD $4,350 More Info
Carcinoembryonic Antigen (CEA): US, Europe, Japan--Market Analysis, Competitive Intelligence, Technology Trends, Opportunities for Suppliers
The cancer diagnostics market is on the verge of explosion, as the researchers approach major techno...
24 Jun 2016 by Venture Planning Group (VPG) USD $4,350 More Info

This report is published by Global Markets Direct

Download Free Report Summary PDF

Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Pipeline Review, H2 2016 | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...